Browse 1,662 uterine cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.
Endometrial cancer, which starts in the lining of the uterus, is the most common gynecologic cancer in the United States and one of the few cancers whose death rate has been rising. The most common early warning sign is bleeding after menopause, which is why it is often found early and treated with surgery. Research matters most for cancer that returns or has spread, where immunotherapy combined with chemotherapy became a standard first treatment only in the past few years, and trials are testing new targeted drugs matched to the tumor's genetic profile.
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
for
Advanced Malignant Solid Neoplasm,
Location: Houston TX
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05111561
Phase 1, Recruiting
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
for
Metastatic Malignant Solid Neoplasm,
Location: Boston MA, Pittsburgh PA, Gainesville FL, Columbus OH,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05372614
Phase 1, Recruiting
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers
Location: Fairfax VA, Plantation FL, Austin TX, San Antonio TX
Sponsor: Conjupro Biotherapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07424547
Phase 1, Recruiting
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
for
Advanced Cancer, Solid Tumor
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT07382544
Phase 1, Recruiting
WellSpan-THRIVE Cancer QOL Study
for
Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative,
Location: Ephrata PA, Lebanon PA, York PA, Gettysburg PA,
Sponsor: WellSpan Health
Sex: All
Age: 18+
Code: NCT07433660
Recruiting
DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer
for
Solid Tumor, Solid Tumor, Adult
Location: Commack NY, Rockville Centre NY, Harrison NY,
Sponsor: Ponce Medical School Foundation, Inc.
Sex: All
Age: 21 - 70+
Code: NCT07225088
Recruiting
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
for
Cancer, Cancer (Solid Tumors)
Location: Fairfax VA, Huntersville NC, Dallas TX
Sponsor: Conjupro Biotherapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07317505
Phase 1, Recruiting
TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
for
Advanced Malignant Solid Neoplasm,
Location: Sacramento CA
Sponsor: University of California, Davis
Sex: All
Age: 18+
Code: NCT07189195
Phase 1, Recruiting
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
for
Cutaneous Squamous Cell Carcinoma,
Location: Uniondale NY, New York NY, Middletown NJ, Montvale NJ,
MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers
for
Metastatic Malignant Solid Neoplasm,
Location: Jacksonville FL
Sponsor: Mayo Clinic
Sex: All
Age: 18+
Code: NCT06911008
Phase 1, Recruiting
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
for
Recurrent Solid Tumor, Recurrent Ewing Sarcoma,
Location: Montreal, Washington D.C. DC, Toronto, Atlanta GA,
Sponsor: St. Jude Children's Research Hospital
Sex: All
Age: 1 - 30
Code: NCT04901702
Phase 1, Phase 2, Recruiting
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
for
Diffuse Midline Glioma, H3 K27-Altered,
Location: Boston MA, Valhalla NY, New York NY, Philadelphia PA,
Sponsor: Children's Oncology Group
Sex: All
Age: 1 - 21
Code: NCT04870944
Phase 1, Phase 2, Recruiting
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)